Loading...
XPAR
ABVX
Market cap484mUSD
Jun 12, Last price  
6.25EUR
1D
-0.30%
1Q
23.19%
Jan 2017
5.40%
IPO
-67.92%
Name

Abivax SA

Chart & Performance

D1W1MN
P/E
—
P/S
85.80
EPS
—
Div Yield, %
—
Shrs. gr., 5y
33.36%
Rev. gr., 5y
203.31%
Revenues
5m
+0.83%
74,87267,13442,000127,00010,00018,00023,00063,00037,0004,583,0004,621,000
Net income
-148m
L+111.52%
-5,893,547-8,099,362-15,954,000-14,308,000-11,223,000-15,823,000-30,634,000-37,551,000-41,357,000-69,846,000-147,740,000
CFO
-154m
L+54.06%
-3,305,008-14,904,000-15,608,000-8,449,000-14,603,000-27,473,000-29,823,000-45,657,000-27,989,000-100,009,000-154,072,000
Earnings
Sep 08, 2025

Profile

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
URL
https://www.abivax.com/
IPO date
Jun 26, 2015
Employees
22
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,621
0.83%
4,583
12,286.49%
Cost of revenue
132,704
98,441
Unusual Expense (Income)
NOPBT
(128,083)
(93,858)
NOPBT Margin
Operating Taxes
(4,493)
(4,476)
Tax Rate
NOPAT
(123,590)
(89,382)
Net income
(147,740)
111.52%
(69,846)
68.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
434
353,387
28,592
BB yield
-83.56%
-20.75%
Debt
Debt current
43,769
10,607
9,491
Long-term debt
55,955
45,396
37,414
Deferred revenue
Other long-term liabilities
18,218
16,153
39
Net debt
(44,623)
(217,285)
19,884
Cash flow
Cash from operating activities
(154,072)
(100,009)
(27,989)
CAPEX
(640)
(266)
(43)
Cash from investing activities
15,762
(10,495)
(513)
Cash from financing activities
28,207
340,569
48,033
FCF
(1,788)
(121,449)
(92,307)
Balance
Cash
144,221
260,992
26,950
Long term investments
126
12,296
71
Excess cash
144,347
273,057
26,792
Stockholders' equity
(438,321)
(282,208)
(148,248)
Invested Capital
594,484
549,834
202,968
ROIC
ROCE
EV
Common stock shares outstanding
43,066
22,301
Price
6.76
-31.16%
9.82
58.90%
6.18
-78.35%
Market cap
422,908
206.85%
137,821
-71.19%
EV
205,623
157,705
EBITDA
1,100
(127,376)
(93,549)
EV/EBITDA
Interest
15,825
3,696
Interest/NOPBT